In a report released yesterday, Daina Graybosch from SVB Securities maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $1.50. The company’s shares opened today at $0.74.
According to TipRanks, Graybosch is an analyst with an average return of -18.5% and a 30.33% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as BioNTech SE, Merck & Company, and Nektar Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Hold with an average price target of $2.75, which is a 271.72% upside from current levels. In a report released on May 9, Jefferies also upgraded the stock to a Hold with a $1.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Nektar Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $22.02 million and a GAAP net loss of $59.69 million. In comparison, last year the company earned a revenue of $24.82 million and had a GAAP net loss of $90.39 million
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
- Nektar Therapeutics Reports First Quarter 2023 Financial Results
- NKTR Earnings this Week: How Will it Perform?
- Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly
- Nektar Chief Medical Officer Brian Kotzin, CFO Jillian Thomsen to step down
- Nektar announces strategic repriotization, to reduce San Francisco staff by 60%
